[Use of flecainide in the preventive treatment of tachycardia crisis of Wolff-Parkinson-White syndrome in 4 newborn infants].
Four neonates with Wolff-Parkinson-White syndrome developed supraventricular tachycardia and received flecainide orally after reduction of the arrhythmia. The initial doses were 5 mg/kg/day. They are increased according to clinical response and flecainide concentrations, with 5 and 10 mg/kg/24 h respectively, were in the therapeutic range of 200 to 1000 micrograms/l. Flecainide was effective and well tolerated in the 4 cases. Therefore, this drug may be an alternative to digoxine to prevent supraventricular tachycardias in the neonatal period.
Lupoglazoff
J M
JM
Département de Pharmacologie Clinique, Paris.
Jacqz-Aigrain
E
E
Denjoy
I
I
Casasoprana
A
A
D005424:Flecainide / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D013617:Tachycardia, Supraventricular / Q000209:etiology / Q000517:prevention & control*; D014927:Wolff-Parkinson-White Syndrome / Q000150:complications* / Q000188:drug therapy
D005424:Flecainide
Utilisation du flécaïnide pour le traitement préventif des crises de tachycardie du syndrome de Wolff-Parkinson-White chez 4 nouveau-nés.